Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength?

Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Jan 30, 2026

Korro Bio, Inc. (KRRO) Analyst/Investor Day Transcript

Korro Bio, Inc. (KRRO) Analyst/Investor Day Transcript

Seeking Alpha • Jan 29, 2026

Korro Bio, Inc. (KRRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Korro Bio, Inc. (KRRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 20, 2026

Korro to Host Virtual Analyst Day on January 27, 2026

- Program to feature presentations from the company management about  KRRO-121 for the potential treatment of hyperammonemia , a leading clinical hepatologist about ammonia-driven diseases, and a caregiver sharing perspectives on living with urea cycle disorder - CAMBRIDGE, Mass., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that the company will host a virtual Analyst Day on Tuesday, January 27, 2026, from 8 a.m.

GlobeNewsWire • Jan 20, 2026

Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 10:30 a.m. PT (1:30 p.m. ET). Todd Chappell, Chief Operating Officer, and Loic Vincent, Ph.D., Chief Scientific Officer, will also be participating at the conference.

GlobeNewsWire • Jan 8, 2026

Korro Bio Plummets To A Record Low On A Big Setback In RNA-Editing

Korro Bio stock plummeted Thursday after its RNA-editing drug failed to pass muster in patients with a rare lung and liver disease.

Investors Business Daily • Nov 13, 2025

Korro Bio Early Trial Results Fall Short; Stock Hits New Low

Korro Bio, Inc. (NASDAQ: KRRO) stock is sinking on Thursday with a session volume of 6.68 million compared to the average volume of 1.42 million, as per data from Benzinga Pro.

Benzinga • Nov 13, 2025

This biotech is halting its work with Novo Nordisk and laying off more people

Korro is the latest to rethink its ties with the Danish pharma company.

Market Watch • Nov 12, 2025

Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs

CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- — KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients     — KRRO-110 did not reach projected levels of functional protein following a single administration      — Pivoting to GalNAc delivery for patients with AATD; development candidate nomination expected in the first half of 2026     — Nominated KRRO-121, designed to create a de novo protein variant to activate a biological pathway for patients with hyperammonemia     — Reports third quarter 2025 financial results; ended third quarter 2025 with $102.5 million in cash, cash equivalents and marketable securities; extending cash runway into second half of 2027 by implementing a strategic restructuring     CAMBRIDGE, Mass.

GlobeNewsWire • Nov 12, 2025

Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates

Korro Bio, Inc. (KRRO) came out with a quarterly loss of $1.92 per share versus the Zacks Consensus Estimate of a loss of $2.61. This compares to a loss of $2.26 per share a year ago.

Zacks Investment Research • Nov 12, 2025